Related Experiment Video
Updated: Jan 17, 2026

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles
Published on: November 10, 2017
Assessing Prescribing Patterns of Nonstatins as Add-on Therapy for Secondary Prevention in a Federally Qualified
Sabrina Guerra1, Kathryn P Lin1,2, Ahmed S Kenawy1
1College of Pharmacy, The University of Texas at Austin, Austin, TX 78712, USA.
Background:
Lipid management is a key aspect of secondary atherosclerotic cardiovascular disease (ASCVD) prevention. However, real-world studies show that ~72-88% of patients with ASCVD fail to meet their low-density lipoprotein cholesterol (LDL-C) target. Nonstatin agents are available as add-on therapies that can be utilized when maximally tolerated statins are insufficient to achieve LDL-C goals. This retrospective study aimed to evaluate the current prescribing habits of nonstatins as add-on therapy to statins for secondary ASCVD prevention at a federally qualified health center (FQHC).
Methods:
Patients were included if they had a history of clinical ASCVD, ≥1 lipid panel obtained during the study period, and were prescribed any intensity statin.
Results:
Among 398 included participants, 11.1% were prescribed nonstatin therapy and 35.9% were meeting a LDL-C target of <70 mg/dL. There was a significant association between being prescribed ezetimibe based on the type of healthcare coverage (p = 0.04) and a higher number of ASCVD qualifying indications (p < 0.01).
Conclusions:
Overall, nonstatins were found to be underutilized for LDL-C management in this underserved population. Future initiatives should target ways to optimize nonstatin therapy to optimize secondary ASCVD prevention.
More Related Videos
Related Concept Videos
Lipid-Lowering Drugs: Statins and Miscellaneous Agents
Atherosclerosis III: Management
Coronary Artery Disease V: Interprofessional Care
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
Acute Coronary Syndrome IV: Interprofessional Care
Coronary Artery Disease IV: Preventive Measures

